Program: 8^th EUROD Winter Meeting January 2025
Theme: Diabetes and CKD(-MBD): Partners in crime

*** Wednesday, Jan 15, 2025 ***

13:00 – 13:10: Welcome (Pieter Evenepoel, UZ/KU Leuven, Belgium)

13:10 – 15:00: Young Investigator Workshop: The utility of DXA imaging in CKD 
Get to know clinical bone imaging in-depth, by rotating through three hands-on sessions of 25 minutes each, with ample time for interaction with the experts.

Chairs: Susa Lloret (Barcelona, Spain)

• 13:15-13:40 Session A (room: Willem Van Croy): Opportunities and pitfalls of DXA in CKD (Marie-Helene Lafage-Proust, St.Etienne, France)
• 13:45-14:10 Session B (room: St. Barbara): Importance of vertebral fracture assessment in CKD (Maria Fusaro, Padua, Italy & Syazrah Salam, Sheffield, UK)
• 14:15-14:40 Session C (room: Anna De Paepe): Novel opportunities with DXA scans; 3D DXA, hip strength analysis, TBS (Andrea Trombetti, Geneva, Switzerland)

14:45 – 15:30: Coffee break 

15:30 – 17:30: Clinical Hot Topics
Chairs: Hanne Skou Jørgensen (Aarhus, Denmark) & Maria Fusaro (Padua, Italy)

• 15:30–15:55 Update from the 2024 KDIGO Controversies Conference on CKD-MBD: Paradigm shifts and future directions (Markus Ketteler, Stuttgart, Germany)
• 16:00–16:25 Nutritional vitamin D in CKD – report from a European consensus (to be confirmed)
• 16:30–16:55 Metabolic acidosis: An appealing therapeutic bone target in CKD and beyond? (Nilufar Mohebbi, Bern, Switzerland)
• 17:00-17:25 Lessons from the osteoporosis world; recent trials of relevance in CKD (Michaël Laurent, AZ Imelda, Bonheiden, Belgium)

18:30: Meet & Greet Leuven (Radiohuis, registration necessary)

*** Thursday, Jan 16, 2025 ***

11:00 – 12:30: Satellite symposium – mineral metabolism and bone in rare renal diseases 

Gain mechanistic insights into mineral and bone disorders by considering how rare renal disease may impact the CKD-MBD syndrome.

Chairs: Justine Bacchetta (Lyon, France)

• 11:05 – 11:25 Bone metabolism in ADPKD (Magdalena Jankovska, Gdańsk, Poland)
• 11:30 – 11:55 The role of RNAi on bone disease in primary hyperoxaluria type 1 (Justine Bacchetta, Lyon, France)
• 12:00 – 12:25 Differential diagnoses of hypophosphatemia (Julien Paccou, Lille, France)

12:30 – 13:30: Lunch

13:30 – 18:00: Research Forum

The EUROD research forum gathers basic and clinical researchers, focusing on scientific progress in renal bone disease. The mission of the EUROD research forum is to share knowledge, foster collaboration, and enhance networking. The EUROD research forum comprises a mixture of invited mini lectures, selected free communications, and short pitches, with ample time for discussion.

13:30 – 15:00: Research Forum part 1 
Chairs: Marie-Hélène Lafage-Proust (St.Etienne, France) & Juan M Diaz Tocados (Lleida, Spain)

• 13:30 – 13:45 (FC): to be determined
• 13:50 – 14:05 (FC): to be determined
• 14:10 – 14:30 (ML): The effect of incretins on skeletal health (Jakob Starup-Linde, Aarhus, Denmark)
• 14:35 – 14:55 (ML): Advanced glycation end-products and bone metabolism (Nicola Napoli, Rome Italy)

15:00 – 16:00: Coffee break and Posters

16:00 – 17:45: Research Forum part 2
Chairs: Nathalie Bravenboer (Amsterdam, The Netherlands) & Anja Verhulst (Antwerp, Belgium)

• 16:00 – 16:20 (ML): Metabolic regulation of skeletal cell fate and function (Steve Stegen, Leuven, Belgium)
• 16:25 – 16:40 (FC): to be determined
• 16:45 – 17:00 (FC): to be determined
• 17:05 – 17:25 (ML): Interaction between glucose and phosphorus metabolism (Martin de Borst, Groningen, the Netherlands)
• 17:30 – 17:50 (P): Calcify2D – a novel technique for simultaneous assessment of vertebral fractures and vascular calcification (Maria Fusaro, Padua, Italy)

17:50: Best Abstracts (Pieter Evenepoel, UZ/KU Leuven, Belgium)

19:00: Social Event (De Optimist, optional) 

*** Friday, Jan 17, 2025 ***

08:30 – 16:00: CME – Diabetes and CKD-MBD: partners in crime

Diabetes mellitus (DM) is not only the most common cause of CKD, it is also a prevalent comorbidity in patients with CKD. DM significantly inflates the risk of vascular calcification and fractures in patients with CKD. Although underlying pathophysiological mechanisms remain largely obscure, mounting evidence points to insulin resistance, advanced glycation end products and cellular senescence as important culprits. A better understanding of these mechanisms may unveil promising therapeutic targets. Meanwhile, the landscape of diabetes treatment in patients with advanced CKD already rapidly evolves. Next to glycemic control, cardiovascular and skeletal protection gain importance when making choices. 

08:30 – 08:45: Welcome (Pieter Evenepoel, UZ/KU Leuven, Belgium)
Chairs: Christa Maes (Leuven, Belgium) & Mathias Haarhaus (Stockholm, Sweden)

08:45 – 10:00: Pathophysiological mechanisms at the crossroad of diabetes and CKD 

• 08:40 – 09:10: Insulin resistance: innocent bystander or mediator of vascular and skeletal disease (Thomas Ebert, Leipzig, Germany)
• 09:20 – 09:50: Advanced glycation end-products: innocent bystanders or mediators of vascular and skeletal disease? (Casper Schalkwijk, Maastricht, the Netherlands) 

10:00 – 10:40 Coffee break

10:40 – 12:30: Impact of diabetes on bone and vascular health
Chairs: Anibal Ferreira (Lisbon, Portugal) & Hanne Skou Jørgensen (Aarhus, Denmark)

• 10:40 – 11:10: Diabetes and bone health in patients with and without CKD (Serge Ferrari, Geneva, Switzerland)
• 11:20 – 11:50 Cross-talk between bone and vasculature in diabetes and CKD (Maria Mace, Copenhagen, Denmark)

12:00 – 13:00: Lunch

13:00 – 15:00: Targeting diabetes and fracture risk in patients with CKD
Chairs: Pieter Evenepoel (Leuven, Belgium) & Syazrah Salam (Sheffield, UK)

• 13:00 – 13:35: Diabetes therapy standards in patients with CKD (Pieter Gillard, Leuven, Belgium)
• 13:45 – 14:05: Effect of antidiabetic treatment on bone (Cristiana Cipriani, Rome, Italy)
• 14:15 – 14:50: How to address fracture risk in diabetic patients? (Richard Eastell, Sheffield, UK) 

15:00: Concluding remarks (Pieter Evenepoel, UZ/KU Leuven, Belgium)

15:15 – 16:00: Coffee and Networking